Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
about
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin forClinical significance of ERCC1, RRM1 and TS in non-small cell lung cancerAdjuvant or neoadjuvant chemotherapy for NSCLC.Liquid biopsy: monitoring cancer-genetics in the blood.Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survivalEconomic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.3',4',5',5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathwayClinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells.LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveObservation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).Role of the stem cell-associated intermediate filament nestin in malignant proliferation of non-small cell lung cancer.Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.Nestin servers as a promising prognostic biomarker in non-small cell lung cancer.Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cellsPemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma.Pattern of Imaging after Lung Cancer Resection. 1992-2005.Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma.Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer.[Long-term survival of a patient with advanced non-small cell lung cancer on bevacizumab therapy: case report and review of the literature].Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.[Correlation between regional node metastasis and imageological characteristics in non-small cell lung cancer].
P2860
Q21261297-2A2447D8-782B-489F-8F87-5DCC2FF77446Q26830488-FCE638B7-434A-43C7-8C3C-D6DCABCD5286Q33658228-2E6C92DE-D2E6-422D-A52F-AE61F3493957Q34356149-04D660BB-0755-4964-B0AA-CAF4CEF0F63DQ34524860-59ED8870-85E6-44A5-BBCF-2455A2E01BAFQ35106391-A2A3EC65-3BD0-4C66-8DC2-2D45EC509496Q35644451-4B6D4F0A-4CC8-4CA2-898A-2E80ADF429A4Q35779978-17F0C4E7-C85C-40CB-B3E9-32DF795BA53DQ36235727-1714674C-4B34-4C52-981C-A4E8A9947FAEQ36530038-E4CE76DC-A686-4FB0-9CED-8EC555B04143Q36862865-F3A88489-AD97-4D4B-9A73-FB7801068884Q37548381-7F98CA2C-2066-4BF1-8112-B8FF1B268A7AQ37645195-D9EBCA0D-0326-4D84-8806-B7E8AE582B32Q37665660-FF88C921-677B-4310-ABB8-C4AE95621B8AQ37733046-0919B731-E200-40C8-8C88-A2D9175D6B03Q38080047-24F5037A-E6A2-45B4-B93A-28EFC84E7AC8Q38099562-8FBF4254-2B52-480E-980C-5AA17BEBDAE5Q38825333-0D2E37B0-9AD7-4C50-8753-56F529F6EE84Q39442474-AA100CC9-762D-4083-A5EE-638B4F43DE64Q39639581-9077186B-7170-4080-A515-C4B362B5362DQ40002473-FC8638E6-6435-425B-9278-5B33043ECB59Q40727371-5A53A0C4-60FF-4E3E-ACE8-262A7BF321A1Q41213157-5E9DAC80-7B1A-437A-A08B-A1EFB3C1A072Q41437298-593A92E8-3138-42A5-96D3-36BFB2C20B98Q44008655-549BED89-E512-4815-8142-1248AAB3A590Q49582579-F28D3386-7970-4CED-8FD7-4301622DB177Q52688847-A9C7D320-102A-468D-BFEA-499066EC9531Q55286883-8B7C988E-AE02-4DCA-96FB-0CE26B53B925Q55436834-874E5888-EB86-45AD-8CBD-254E0D0152A9
P2860
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@en
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@nl
type
label
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@en
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@nl
prefLabel
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@en
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@nl
P2093
P356
P1433
P1476
Non-small-cell lung cancer: ES ...... osis, treatment and follow-up.
@en
P2093
ESMO Guidelines Working Group
G D'Addario
P356
10.1093/ANNONC/MDP132
P478
20 Suppl 4
P577
2009-05-01T00:00:00Z